A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
about
Proteomic-Based Approaches for the Study of Cytokines in Lung CancerCytokine-Induced Modulation of Colorectal CancerIL-6 Plays a Crucial Role in HBV InfectionWound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancerImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaSiltuximab (CNTO 328): a promising option for human malignanciesTargeted immune therapy of ovarian cancerPhase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumorModulation of hepcidin to treat iron deregulation: potential clinical applications.Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.Therapeutic targets and new directions for antibodies developed for ovarian cancer.Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation.The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis.Emerging cytokine networks in colorectal cancer.Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Loss of dual-specificity phosphatase-2 promotes angiogenesis and metastasis via up-regulation of interleukin-8 in colon cancer.Paraneoplastic thrombocytosis in gastrointestinal cancer.Addressing intra-tumoral heterogeneity and therapy resistance.Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.Pharmacological and immunological targeting of tumor mesenchymalization.Targeting cancer-related inflammation in the era of immunotherapy.A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.Tumor-Associated Macrophages as Target for Antitumor Therapy.Gram-positive pneumonia augments non-small cell lung cancer metastasis via host toll-like receptor 2 activation.Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer.How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair.The role of macrophage phenotype in regulating the response to radiation therapy.Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.Strategies for Increasing Pancreatic Tumor Immunogenicity.
P2860
Q26738539-5F75891E-2CDC-46DB-92AC-51206BDAB4F9Q26752374-400CE4D1-C503-4514-A9E4-1AFB1EB654AFQ26774879-126A170E-3F91-4A0D-B870-EB6BBDB03227Q27023599-650CB6C0-C4EA-4EE1-8955-FC4288DC2D35Q28069864-647252CA-875D-4198-87FB-DB2283E21C8FQ28082572-570F4002-DAA6-4CFB-8E26-F6D5FC178C4DQ28082828-790A3AFB-B0AD-42BC-930A-8F6DA292E6C7Q33420197-24C2B103-16FB-42AC-BF9C-83FEAF249C7DQ36528333-A853483D-B28B-4803-ABB2-F33A4A111E53Q36847852-18644CA9-BF1E-44D0-83A6-6B47F16A0679Q36902015-7A11DE34-5845-42EA-BEE6-029B161CA8CAQ37397674-7BEF2473-ABBC-4F4E-B37C-07DEE80BBE2BQ37582274-635FB305-578D-41A9-9AAD-FA506765976BQ38328376-7AF6ADC3-F99F-40C0-B8B8-2BA21E759E11Q38336406-128D72F6-819E-4BF1-B5CB-256E606EB6D2Q38584430-F3D893CA-E0F4-428C-B9A9-0C8D72F5FB46Q38658328-21DDC0FF-AB82-4E95-92AE-29F8FA4F079CQ38715211-037D4635-4AF4-4761-85DD-0B2F5932DA5BQ38724150-32389FDB-C06A-4348-B760-4703CF2F10F6Q38823142-D536D27F-778C-4E9E-9131-2A7B885FC13CQ38823179-5B005EE3-C39E-4994-92BE-28871F2FAF6CQ38889364-BD1E4DA4-D8C8-4278-BE82-E18C2DDEE537Q38930155-E7F34885-AA3A-4A2C-8AE3-70CD2D40DF3FQ39029043-611D4602-E0E4-4FBB-B24D-D62873F48A1EQ39044981-BDA5391C-04EA-4401-BA54-E0F8C105D90BQ39182177-6C4281DF-4A4E-43E5-8282-B7475D6AE290Q39403895-1F6B1C99-4598-4775-8D0E-EC3F11751C0AQ40254726-55F04D37-3CFC-4552-8D88-1A59FE41EECBQ40433122-4985A104-2AE5-4189-AE6A-5B3E2683766DQ42288627-5E1D976C-5AF3-4F0C-B170-CF6D67D3DA39Q42360448-7E84A585-21B4-458E-B1AA-3BB89A9F47C1Q47601253-4FCE665B-13A2-4F21-82C0-355D4F1A8EAFQ49634844-E97B2B26-ABF9-464C-ABC4-0D661A25A68EQ50066081-A5A5D739-45A9-49AB-BC99-BF7353232356Q50191433-EB537C6C-47E5-40F7-92A6-45C07663CF4AQ50892802-6136E9A9-B863-4260-B159-CCBD1FD1028AQ51176869-F6E1B221-DE97-4C75-A2E4-87F64D215133Q52540247-C8485A8C-7BA0-4CC5-94E7-FDA3B22EDCB6Q52560420-9B6F0D34-BFDF-47FC-9950-AEDF6A32B10EQ52691832-B4CF1347-372A-4A22-98A4-4954BC89F7A9
P2860
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@en
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@nl
type
label
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@en
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@nl
prefLabel
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@en
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@nl
P2093
P50
P1476
A phase I/II, multiple-dose, d ...... ts with advanced solid tumors.
@en
P2093
Brenda Tromp
Brett Hall
Elena Elez
Helgi van de Velde
Isabelle Ray-Coquard
Jean-Luc van Laethem
Jean-Pascal Machiels
Jessica Vermeulen
Manjula Reddy
P304
P356
10.1158/1078-0432.CCR-13-2200
P407
P577
2014-02-21T00:00:00Z